Back to Search
WESLEY MERRITT, M.D.
M.D.
Specialist
NPI: 1396700571IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anesthesiology Physician
Anesthesiology
Code: 207L00000X
L9810(TX)
SpecialistPrimary
Specialist
Code: 174400000X
L9810(TX)
CMS Specialties
PrimaryANESTHESIOLOGY
Education
UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Class of 2000
Research & Publications (20)
Dicer, Drosha, and outcomes in patients with ovarian cancer.
PMID 19092150·N Engl J Med·2008
4-observational
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
PMID 18314475·J Natl Cancer Inst·2008
7-preclinical
Functional significance of VEGFR-2 on ovarian cancer cells.
PMID 19058181·Int J Cancer·2009
7-preclinical
Modification of blood vessel diameter following perivascular application of botulinum toxin-A.
PMID 19194764·Hand (N Y)·2009
8-other
Effects of perivascular Botulinum Toxin-A application on vascular smooth muscle and flap viability in the rat.
PMID 19387141·Ann Plast Surg·2009
4-observational
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
PMID 19396818·Cancer·2009
8-other
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
PMID 18443215·Blood·2008
8-other
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
PMID 18519766·Clin Cancer Res·2008
8-other
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
PMID 18632639·Cancer Res·2008
7-preclinical
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
PMID 18765535·Clin Cancer Res·2008
7-preclinical
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.
PMID 18953435·Neoplasia·2008
7-preclinical
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
PMID 18395047·Am J Obstet Gynecol·2008
7-preclinical
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
PMID 18765538·Clin Cancer Res·2008
7-preclinical
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
PMID 17634550·Clin Cancer Res·2007
8-other
NMR analysis of [methyl-13C]methionine UvrB from Bacillus caldotenax reveals UvrB-domain 4 heterodimer formation in solution.
PMID 17822711·J Mol Biol·2007
8-other
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
PMID 17909042·Cancer Res·2007
7-preclinical
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
PMID 18006843·Cancer Res·2007
7-preclinical
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
PMID 18094433·Clin Cancer Res·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 1111 RAINTREE CIR, STE. 170
ALLEN, TX 75013 - Phone
- (214) 509-9691
Quick Facts
- NPI
- 1396700571
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 3
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile